FDA Proposes Rule for Hub-and-Spoke Drug Manufacturing Registration

The FDA has proposed a new rule that would simplify the registration for drug manufacturers using a hub-and-spoke model, allowing them to register as a single facility. This change aims to reduce administrative burdens and improve the efficiency of the drug supply chain. The rule also introduces guidelines for foreign establishments producing medicines solely for overseas use, requiring them to register with the FDA. Finalizing this rule would enhance FDA's oversight on drug origins and improve safety responses, which is important for consumers and the pharmaceutical market.